Thus, MVA-based, IL-15 coexpressing candidate malaria vaccines may have an impact on malaria-related morbidity and mortality in endemic areas by reducing levels of blood-stage parasites despite an inability to induce sterile immunity. This evidence concerns the gene IL15 and malaria.